Trial Profile
Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions
- 08 Jun 2022 Primary endpoint has not been met. (change in eGFR at 2 years post-transplant in Tac+MPA), as per Results presented at the 2022 American Transplant Congress
- 08 Jun 2022 Results presented at the 2022 American Transplant Congress
- 08 Dec 2020 Status changed from recruiting to completed.